19 Sep 2022

NEWS RELEASE: Eremid Genomic Services founded following VC investment



Alto Marketing:

Omee Ahmed – Senior Manager; E: omeea@alto-marketing.com; T: +44(0)1489 557672
Eremid® Genomic Services, LLC:
Julian Abery – Chief Business Officer; E: JAbery@eremid.com; T: +1 (704) 706 5051
Coddle Creek Capital, LLC:
John Allen – General Partner; E: jallen@coddlecapital.com; T: +1 (704) 907 1276


Eremid® Genomic Services founded following VC investment as
cornerstone of expanding biotech hub

Venture capital firm, Coddle Creek Capital, invests in CRO to expand
capabilities and deliver exceptional quality, data, and service to the genomics

Key members of Eremid® and Coddle Creek Capital teams

KANNAPOLIS, NC, USA (September 20, 2022) –  Eremid® Genomic Services, LLC (“Eremid”), formerly Eremid Research Services, Inc., has been acquired by Coddle Creek Capital (“CCC”) and is under new commercial management.  CCC has made a multi-million-dollar investment in Eremid, enabling an expanded research offering focused on the intersection of genomics in the areas of human health, agriculture, plant based nutrition and longevity. Coddle Creek Capital is an early-stage life science venture capital fund partnering with academic Principal Investigators to move their research into commercial enterprises. Focusing on quality and service, customers can expect Eremid’s world-class scientific staff to deliver high-quality data using the latest generation of genomics instruments and automation, meeting a growing demand for high-end genomics/research across multiple markets. The company will be a key partner and resource for the rapidly growing biotech hub being built on the North Carolina Research Campus, and for the local and wider genomics community.

Originally spun out as the commercial arm of the David H. Murdock Research Institute, the new investment from CCC will see Eremid refocus on becoming a high-end, scientifically driven genomics partner. Boosted by rapidly-evolving Next Generation Sequencing technologies, research and applications in this growing branch of molecular biology increasingly demand higher quality, reliability, and accuracy in data and interpretation. Eremid’s goal is to provide access to and guidance on better use of these technologies, and its experience in delivering complex genomics projects and bioinformatic analyses places it as the perfect CRO partner to meet this need.

In addition to Eremid, CCC has been a key investor, advisor and/or founder of several co-located companies that will form part of the expanding biotech hub, including:

  • BrightPath Labs: A highly advanced AI-driven drug manufacturer accelerating US Pharmaceutical independence via advanced manufacturing technology.
  • Salubrent Pharma Services: An analytical and consultation services CDMO focused on advancing the aseptic sterile fill & finish formulation and manufacturing sector.
  • SNP Therapeutics: A Precision Nutrition company, spun out from the University of North Carolina Chapel Hill Nutritional Research Institute in Kannapolis, NC.

Adding a new and already successful company to its portfolio will bolster Coddle Creek Capital’s position as an early phase investor and help the new biotech hub gain traction.

Julian Abery, Chief Business Officer at Eremid commented: “This is an exciting time of growth and development for us. With the support of Coddle Creek Capital, Eremid promises to become a best-in-class genomics CRO. We will deliver scientific excellence to our customers by leveraging decades of research experience and the latest technologies, while making no compromises in our processes. We will focus on areas that influence human health and longevity, including agbiotech, nutrition, and immunooncology research.”

John Allen, General Partner at Coddle Creek Capital, added: “I’m delighted for us to add Eremid Genomic Services to our portfolio. Eremid already provides high-end NGS services to the market, meeting a demand for absolute expertise, reliability, and data quality. With our investment, the company will be able to leverage its expertise and instrumentation to provide a truly exceptional service to the wider genomics community and help catalyze further developments in the local area.”

For more information on Eremid Genomic Services, visit https://eremid.com.

Editor’s notes

Eremid® Genomic Services, LLC

Eremid® Genomic Services is a high-end genomics contract research organization, focusing on science that influences human health and longevity. The company offers specialist expertise in human health, nutrition, and agbiotech, delivering high quality research-enhancing data through customized, collaborative projects. Eremid has invested in world-class scientific staff, and cutting-edge genomic instrumentation and automation to create a unique offering that meets the increasing demands for higher data quality, reliability, and accuracy in genomics research. The company forms the cornerstone of a biotech hub based on the North Carolina Research Campus, offering collaboration and partnership opportunities, and serving both the local and wider scientific communities.

Coddle Creek Capital

Coddle Creek Capital is a life science venture capital firm focused on evaluating academic IP and initiating the first commercial efforts including corporate formation, seed investment, commercial management and capital raising.  Sectors of investment include genomics, nutrition, oncology, immunology, microbiome and neurology.  The firm focuses on commercializing innovations in the underserved markets of New Mexico and North Carolina. It embraces companies that invest in exceptional teams and big ideas that capitalize on emerging trends in the healthcare landscape.   The fund invests in early-stage growth companies that have demonstrated scientific proof-of-concept and are looking to demonstrate commercial proof-of-concept.



Looking for deeper insights on your next project? Discuss a project
"Eremid provides the support we need to make a global impact in our large immunogenomic oncology clinical studies. The team’s expertise and flexibility from assay design to data delivery is helping us achieve our vision – an ideal research partner." Geoffrey Erickson, Immunis AI, MI USA — Senior Vice President, Corporate Development
"Working with Eremid has been a pleasure. We received excellent data with a very fast turnaround and appreciated the attentive and helpful project management!" Steve Watkins, BCD Biosciences, CA USA — CEO
Trusted by